MoonLake Immunotherapeutics reports results for the quarter ended September 30 - Earnings Summary

MoonLake Immunotherapeutics

Wed 13:39

MoonLake Immunotherapeutics MLTX.OQ reported a quarterly adjusted loss of 93 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.10.  The mean expectation of thirteen analysts for the quarter was for a loss of 78 cents per share. Wall Street expected results to range from -95 cents to -66 cents per share.
Reported revenue was zero​; analysts expected zero. 
MoonLake Immunotherapeutics's reported EPS for the quarter was a loss of 93 cents​.
The company reported a quarterly loss of $79.55 million.
MoonLake Immunotherapeutics shares had held steady so far this quarter and lost 11.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 14.7% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $30.00, about 61% above its last closing price of $11.70
This summary was machine generated from LSEG data November 4 at 01:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.78
-0.93
Missed
Jun. 30 2026 
-0.92
-0.84
Beat
Mar. 31 2026 
-0.89
-0.98
Missed
Dec. 31 2025 
-0.99
-0.92
Beat